BioScrip Schedules Release of Fourth Quarter and Full Year 2017 Financial Results and Conference Call

DENVER--()--BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the Company will issue its financial results press release for the fourth quarter and full year ended December 31, 2017 on Thursday, March 8, 2018 before the opening of the U.S. financial markets.

Daniel E. Greenleaf, President and Chief Executive Officer, and Stephen Deitsch, Senior Vice President, Chief Financial Officer and Treasurer, will host a conference call as follows:

   
Date March 8, 2018
Time 9:00 a.m. ET
Toll free (U.S.) (877) 423-9820
International (201) 493-6749
Webcast (live and replay)

www.investorcalendar.com/event/26127

or

www.bioscrip.com

 

The online replay will be available within two hours of the call’s completion in the Investor Relations section of BioScrip’s web site at: www.bioscrip.com.

About BioScrip, Inc.

BioScrip, Inc. is the largest independent national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Contacts

Investors:
BioScrip, Inc.
Stephen Deitsch, 720-697-5200
Chief Financial Officer & Treasurer
stephen.deitsch@bioscrip.com
or
The Equity Group
Kalle Ahl, CFA, 212-836-9614
kahl@equityny.com

Contacts

Investors:
BioScrip, Inc.
Stephen Deitsch, 720-697-5200
Chief Financial Officer & Treasurer
stephen.deitsch@bioscrip.com
or
The Equity Group
Kalle Ahl, CFA, 212-836-9614
kahl@equityny.com